Immunomedics Competitors and Similar CompaniesClear all
Immunomedics's competitors and similar companies include ImmunoGen, AstraZeneca, Seagen, Daiichi Sankyo, Bristol Myers Squibb, Astellas Pharma, AbbVie and ADC Therapeutics.
 Immunomedics Immunomedics is a developer of monoclonal antibody-based products for the targeted treatment of cancer. |  ImmunoGen ImmunoGen is a biotechnology company focused on the development of antibody-drug conjugates (ADCs) to improve outcomes for cancer patients. |  AstraZeneca AstraZeneca is a biopharmaceutical company specializing in the discovery, development, manufacturing, and marketing of prescription medicines. |  Seagen Seagen (formerly known as Seattle Genetics) is a biotechnology company that develops and commercializes targeted therapies to treat cancer. |  Daiichi Sankyo Daiichi Sankyo (第一三共株式会社) is a company specializing in the research, development, and manufacture of innovative pharmaceutical products. |  Bristol Myers Squibb Bristol-Myers Squibb (BMS) is a company engaged in the discovery, development, licensing, manufacturing, marketing, and distribution of biopharmaceutical products. |  Astellas Pharma Astellas Pharma (アステラス製薬株式会社) is a pharmaceutical company focused on the development of drugs and medical solutions. |  AbbVie AbbVie is a pharmaceutical company engaged in the research, development, manufacturing, commercialization, and sale of medicines and therapies. |  ADC Therapeutics ADC Therapeutics is a biotechnology company that develops drug conjugates for the treatment of both solid and haematological cancers. | |
Founding Date | Founding Date 1982 | Founding Date 1981 | Founding Date 1999 | Founding Date 1998 | Founding Date 2005 | Founding Date 1887 | Founding Date 1923 | Founding Date 2013 | Founding Date 2010 |
Type | Type Subsidiary | Type Public | Type Public | Type Subsidiary | Type Public | Type Public | Type Public | Type Public | Type Public |
Tags | |||||||||
Locations | Locations Morris Plains, US HQ | Locations Waltham, US HQ | Locations Cambridge, GB HQ Alger, DZ Buenos Aires, AR Macquarie Park, AU Macquarie Park, AU North Ryde, AU Wien, AT see more | Locations Bothell, US HQ Mississauga, CA Hørsholm, DK Rueil Malmaison, FR München, DE Milano, IT Schiphol, NL see more | Locations Tokyo, JP HQ Macquarie Park, AU Wien, AT Braine L'alleud, BE Sao Paulo, BR Toronto, CA Shanghai, CN see more | Locations Princeton, US HQ Mulgrave, AU Pinewood, AU Wien, AT Braine L'alleud, BE Bruxelles, BE São Paulo, BR see more | Locations Tokyo, JP HQ Macquarie Park, AU Wien, AT Vilvoorde, BE São Paulo, BR Markham, CA Beijing, CN see more | Locations North Chicago, US HQ Alger, DZ Buenos Aires, AR Mascot, AU Wien, AT Wavre, BE Sarajevo, BA see more | Locations Epalinges, CH HQ London, GB New Providence, US |
Employees | Employees 1041% decrease | Employees 277161% increase | Employees 94,3005% increase | Employees 3,25622% increase | Employees 18,726 | Employees 34,100 | Employees 14,754 | Employees 50,000 | Employees 1162% increase |
Valuation ($) | Valuation ($) N/A | Valuation ($) 8.7 b | Valuation ($) 2.7 b | Valuation ($) N/A | Valuation ($) 61.7 b | Valuation ($) 97.8 b | Valuation ($) 20.8 b | Valuation ($) 335 b | Valuation ($) 295.9 m |
Financial | |||||||||
Revenue (est.) | Revenue (est.) $295k (FY, 2019) | Revenue (est.) $108.8m (FY, 2022) | Revenue (est.) $54.1b (FY, 2024) | Revenue (est.) $2b (FY, 2022) | Revenue (est.) ¥1t (FY, 2021) | Revenue (est.) $48.3b (FY, 2024) | Revenue (est.) ¥1.6t (FY, 2024) | Revenue (est.) $56.3b (FY, 2024) | Revenue (est.) $69.6m (FY, 2023) |
Cost of goods | Cost of goods N/A | Cost of goods $176k (FY, 2022) | Cost of goods $9b (FY, 2024) | Cost of goods $410.1m (FY, 2022) | Cost of goods ¥353.3b (FY, 2021) | Cost of goods $14b (FY, 2024) | Cost of goods ¥134.6b (FY, 2024) | Cost of goods $16.9b (FY, 2024) | Cost of goods $1.3m (FY, 2023) |
Gross profit | Gross profit $295k (FY, 2019) | Gross profit $108.6m (FY, 2022) | Gross profit $45.4b (FY, 2024) | Gross profit $1.6b (FY, 2022) | Gross profit ¥691.6b (FY, 2021) | Gross profit $34.3b (FY, 2024) | Gross profit ¥1.5t (FY, 2024) | Gross profit $39.4b (FY, 2024) | Gross profit $68.2m (FY, 2023) |
Net income | Net income ($357.3m) (FY, 2019) | Net income ($222.9m) (FY, 2022) | Net income $7b (FY, 2024) | Net income ($610.3m) (FY, 2022) | Net income ¥67b (FY, 2021) | Net income ($8.9b) (FY, 2024) | Net income ¥17b (FY, 2024) | Net income $4.3b (FY, 2024) | Net income ($234.5m) (FY, 2023) |
Operating ⚠ | |||||||||
Countries | Countries N/A | Countries N/A | Countries 130 (FY, 2021) | Countries N/A | Countries N/A | Countries N/A | Countries N/A | Countries 70 (FY, 2022) | Countries N/A |
Manufacturing Facilities | Manufacturing Facilities N/A | Manufacturing Facilities N/A | Manufacturing Facilities N/A | Manufacturing Facilities N/A | Manufacturing Facilities 13 (Jun, 2022) | Manufacturing Facilities 8 (FY, 2021) | Manufacturing Facilities N/A | Manufacturing Facilities 19 (FY, 2022) | Manufacturing Facilities N/A |
Patent Applications | Patent Applications N/A | Patent Applications 600 (FY, 2020) | Patent Applications N/A | Patent Applications N/A | Patent Applications 367 (Jun, 2022) | Patent Applications N/A | Patent Applications N/A | Patent Applications N/A | Patent Applications N/A |
Phase I Trials Products (Immunology) | Phase I Trials Products (Immunology) N/A | Phase I Trials Products (Immunology) N/A | Phase I Trials Products (Immunology) N/A | Phase I Trials Products (Immunology) N/A | Phase I Trials Products (Immunology) N/A | Phase I Trials Products (Immunology) 6 (FY, 2021) | Phase I Trials Products (Immunology) 1 (Oct, 2020) | Phase I Trials Products (Immunology) N/A | Phase I Trials Products (Immunology) N/A |
Phase I Trials Products (Oncology) | Phase I Trials Products (Oncology) N/A | Phase I Trials Products (Oncology) N/A | Phase I Trials Products (Oncology) N/A | Phase I Trials Products (Oncology) N/A | Phase I Trials Products (Oncology) N/A | Phase I Trials Products (Oncology) 20 (FY, 2021) | Phase I Trials Products (Oncology) 1 (FY, 2020) | Phase I Trials Products (Oncology) N/A | Phase I Trials Products (Oncology) N/A |
Phase II Trials Products (Immunology) | Phase II Trials Products (Immunology) N/A | Phase II Trials Products (Immunology) N/A | Phase II Trials Products (Immunology) N/A | Phase II Trials Products (Immunology) N/A | Phase II Trials Products (Immunology) N/A | Phase II Trials Products (Immunology) 6 (FY, 2021) | Phase II Trials Products (Immunology) 1 (Oct, 2020) | Phase II Trials Products (Immunology) N/A | Phase II Trials Products (Immunology) N/A |
Phase II Trials Products (Oncology) | Phase II Trials Products (Oncology) N/A | Phase II Trials Products (Oncology) N/A | Phase II Trials Products (Oncology) N/A | Phase II Trials Products (Oncology) N/A | Phase II Trials Products (Oncology) N/A | Phase II Trials Products (Oncology) 15 (FY, 2021) | Phase II Trials Products (Oncology) 1 (FY, 2020) | Phase II Trials Products (Oncology) N/A | Phase II Trials Products (Oncology) N/A |
Phase III Trials Products (Immunology) | Phase III Trials Products (Immunology) N/A | Phase III Trials Products (Immunology) N/A | Phase III Trials Products (Immunology) N/A | Phase III Trials Products (Immunology) N/A | Phase III Trials Products (Immunology) N/A | Phase III Trials Products (Immunology) 3 (FY, 2021) | Phase III Trials Products (Immunology) 1 (Oct, 2020) | Phase III Trials Products (Immunology) N/A | Phase III Trials Products (Immunology) N/A |
Phase III Trials Products (Oncology) | Phase III Trials Products (Oncology) N/A | Phase III Trials Products (Oncology) N/A | Phase III Trials Products (Oncology) N/A | Phase III Trials Products (Oncology) N/A | Phase III Trials Products (Oncology) N/A | Phase III Trials Products (Oncology) 7 (FY, 2021) | Phase III Trials Products (Oncology) 4 (Oct, 2020) | Phase III Trials Products (Oncology) N/A | Phase III Trials Products (Oncology) N/A |
Product Categories | Product Categories N/A | Product Categories N/A | Product Categories N/A | Product Categories 4 (Q3, 2023) | Product Categories N/A | Product Categories N/A | Product Categories N/A | Product Categories 6 (FY, 2022) | Product Categories N/A |
Research and Development Centers | Research and Development Centers N/A | Research and Development Centers N/A | Research and Development Centers N/A | Research and Development Centers N/A | Research and Development Centers N/A | Research and Development Centers 11 (FY, 2021) | Research and Development Centers N/A | Research and Development Centers 14 (FY, 2020) | Research and Development Centers N/A |
Funding | |||||||||
Total funding raised | Total funding raised $ 30m | Total funding raised $ 56m | Total funding raised $ 1b | Total funding raised $ 164m | Total funding raised N/A | Total funding raised $ 15.5m | Total funding raised N/A | Total funding raised N/A | Total funding raised $ 526m |
For sources of this data, please see the company profile
View Company Profiles
ImmunoGen
HQ
Waltham, US
Employees
277
ImmunoGen is a biotechnology company focused on the development of antibody-drug conjugates (ADCs) to improve outcomes for cancer patients.
View companyAstraZeneca
HQ
Cambridge, GB
Employees
94,300↑ 5% increase
AstraZeneca is a biopharmaceutical company specializing in the discovery, development, manufacturing, and marketing of prescription medicines.
View companySeagen
HQ
Bothell, US
Seagen (formerly known as Seattle Genetics) is a biotechnology company that develops and commercializes targeted therapies to treat cancer.
View companyDaiichi Sankyo
HQ
Tokyo, JP
Employees
18,726
Daiichi Sankyo (第一三共株式会社) is a company specializing in the research, development, and manufacture of innovative pharmaceutical products.
View company